The active component in this medication is Gefitinib. It shows an antineoplastic activity. This active component inhibits the catalytic activity of numerous tyrosine kinases such as the epidermal growth factor receptor, which may result in inhibition tumor growth. This active agent competes with the binding of ATP to the tyrosine kinase domain of EGFR. It is due to the inhibition of receptor autophosphorylation and leads to inhibition of signal transduction.
It is an EGFR kinase inhibitor used to treat non-small cell lung cancer. It plays the role of an epidermal growth factor receptor antagonist and an antineoplastic agent.
This active component of this medicine is indicated for the treatment of lung cancer. It acts by slowing or stopping the growth of cancer cells. It blocks a certain protein or an enzyme called tyrosine kinase. Iressa can be used in the treatment of non-small cell lung cancer that has spread into the surrounding tissues or to other parts of the body. It is also used in clinical trials for other cancer types.
Gefitinib composed medication is a type of targeted cancer drug called a tyrosine kinase inhibitor (TKI). This tyrosine kinase is a type of protein that sends signals to the cancer cells to grow. Iressa medication bocks these signals. For this medication to work the cancer cells need to have receptors for a protein called epidermal growth factor.
Given cancer-treating medication is available in a conventional tablet form for oral administration. The available dosage is as follows:
- 250 mg: Consume this medication with or without food as advised by the doctor, usually once a day
If consuming PPIs like omeprazole, lansoprazole this medication should be taken at least 12 hours before or 12 after the PPI.